TY - JOUR
T1 - A Proposal from the Montpellier World Health Organization Collaborating Centre for Better Management and Prevention of Anaphylaxis
AU - Tanno, Luciana Kase
AU - Touati, Nidhal
AU - Allichon, Salome
AU - Martin, Bryan
AU - Ebisawa, Motohiro
AU - Ansotegui, Ignacio
AU - Sanchez-Borges, Mario
AU - Cardona, Victoria
AU - Greenberger, Paul A.
AU - Ryan, Dermot
AU - Pouessel, Guillaume
AU - Beaudouin, Etienne
AU - Renaudin, Jean Marie
AU - Thien, Francis
AU - Chang, Yoon Seok
AU - Pawankar, Ruby
AU - Gomez, Maximiliano
AU - Jares, Edgardo
AU - Staffeld, Patricia Latour
AU - Agache, Ioana
AU - Muraro, Antonella
AU - Mahr, Todd A.
AU - Sublett, James
AU - Casale, Thomas
AU - Lang, David
AU - Demoly, Pascal
N1 - Publisher Copyright:
© 2020
PY - 2021/2
Y1 - 2021/2
N2 - Since the first description of anaphylaxis in 1902, its clinical importance as an emergency condition has been recognized worldwide. Anaphylaxis is a severe, potentially life-threatening systemic hypersensitivity reaction characterized by rapid onset and the potential to endanger life through respiratory or circulatory compromise. It is usually, although not always, associated with skin and mucosal changes. Although the academic/scientific communities have advocated to promote greater awareness and protocols for the management of anaphylaxis based on best evidence, there are few efforts documenting feedback as to the success of these efforts. In this article, we review the key unmet needs related to the diagnosis and management of anaphylaxis, and propose a public health initiative for prevention measures and a timetable action plan that intends to strengthen the collaboration among health professionals and especially primary care physicians dealing with anaphylaxis, which can encourage enhanced quality of care of patients with anaphylaxis. More than calling for a harmonized action for the best management of anaphylaxis to prevent undue morbidity and mortality, the Montpellier World Health Organization Collaborating Centre here proposes an action plan as a baseline for a global initiative against anaphylaxis. We strongly believe that these collaborative efforts are a strong public health and societal priority that is consistent with the overarching goals of providing optimal care of allergic patients and best practices of allergology.
AB - Since the first description of anaphylaxis in 1902, its clinical importance as an emergency condition has been recognized worldwide. Anaphylaxis is a severe, potentially life-threatening systemic hypersensitivity reaction characterized by rapid onset and the potential to endanger life through respiratory or circulatory compromise. It is usually, although not always, associated with skin and mucosal changes. Although the academic/scientific communities have advocated to promote greater awareness and protocols for the management of anaphylaxis based on best evidence, there are few efforts documenting feedback as to the success of these efforts. In this article, we review the key unmet needs related to the diagnosis and management of anaphylaxis, and propose a public health initiative for prevention measures and a timetable action plan that intends to strengthen the collaboration among health professionals and especially primary care physicians dealing with anaphylaxis, which can encourage enhanced quality of care of patients with anaphylaxis. More than calling for a harmonized action for the best management of anaphylaxis to prevent undue morbidity and mortality, the Montpellier World Health Organization Collaborating Centre here proposes an action plan as a baseline for a global initiative against anaphylaxis. We strongly believe that these collaborative efforts are a strong public health and societal priority that is consistent with the overarching goals of providing optimal care of allergic patients and best practices of allergology.
KW - Adrenaline/epinephrine autoinjector
KW - Anaphylaxis
KW - Classification
KW - Epidemiology
KW - Management
KW - Prevention
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85095943560&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85095943560&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2020.09.062
DO - 10.1016/j.jaip.2020.09.062
M3 - Article
C2 - 33059097
AN - SCOPUS:85095943560
SN - 2213-2198
VL - 9
SP - 676-683.e1
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 2
ER -